Bristol-Myers Squibb Asked to Lower HIV Drug Prices

Treating HIV is a long, never-ending, and expensive journey, mainly of because the medications needed to temporarily hold the spread of the virus. This is why government officials and HIV/AIDS advocates has asked Bristol-Myers Squibb to have the prices of its HIV-related medication.

Weeks ago, Controller John Chiang sent a letter asking BMS to join other pharmaceutical companies that have already reduced the cost of their drugs. Meanwhile, CalPERS and California State Teachers’ Retirement System have also asked the company to cut the prices of Reyataz.

BMS sales representatives are even banned from visiting clinics under the AIDS Healthcare Foundation unless their firm gives in to the growing demands of reducing the prices of its antiretroviral drugs.

Despite numerous requests, BMS still holds back on their original pricing schemes, which means medicine still costs more. However, the company claims that it already provides several assistance programs and assures the HIV positive patients that it has not turned its back on patients with HIV/AIDS.

Source: California Healthline

 
Responses are currently closed, but you can trackback from your own site.